PMID- 15866696
OWN - NLM
STAT- MEDLINE
DCOM- 20060615
LR  - 20050503
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 66
IP  - 4
DP  - 2005 Apr
TI  - Preformed cytotoxic antibodies in potential allograft recipients: recent data.
PG  - 343-9
AB  - Presensitization to donor human leukocyte antigen (HLA) remains a major barrier 
      to cell and organ transplantation, thereby contributing to patient mortality. The 
      risks associated with transplantation in the presence of preformed antidonor HLA 
      antibodies range from hyperacute rejection and increased frequency and severity 
      of rejection to no appreciable effect on transplant outcome. Recent evidence has 
      emphasized the importance of immunologic history, anti-HLA antibody class and 
      titer, and differential organ susceptibility to antibody-mediated damage to 
      explain differences in risk for antibody-mediated rejection. Furthermore, in 
      studies of endothelial cells, ligation of class I molecules by subsaturating 
      concentrations of antibodies stimulated expression of cell survival proteins, 
      raising the possibility that, under certain conditions, antibodies promote graft 
      accommodation providing a mechanism for the endothelium to resist immune and 
      inflammatory damage. The discovery of capillary-bound C4d as a robust diagnostic 
      marker for antibody-mediated rejection, coupled with the development of 
      solid-phase assays for the identification of HLA-specific antibodies, has 
      enhanced our ability to detect antibody-mediated rejection and interpret 
      cross-match results. With new diagnostic tools and immunosuppression regimens 
      such as plasmapheresis and intravenous immunoglobulin therapy targeting the 
      humoral immune response, it is time for a concerted effort to reassess the role 
      of alloantibodies in acute and chronic rejection.
FAU - Cecka, J Michael
AU  - Cecka JM
AD  - UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, 
      David Geffen School of Medicine, University of California Los Angeles, Los 
      Angeles, CA 90095, USA. mcecka@ucla.edu
FAU - Zhang, Qiuheng
AU  - Zhang Q
FAU - Reed, Elaine F
AU  - Reed EF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Isoantibodies/*toxicity
MH  - Transplantation, Homologous/*immunology/*pathology
RF  - 55
EDAT- 2005/05/04 09:00
MHDA- 2006/06/16 09:00
CRDT- 2005/05/04 09:00
PHST- 2004/12/17 00:00 [received]
PHST- 2005/01/19 00:00 [accepted]
PHST- 2005/05/04 09:00 [pubmed]
PHST- 2006/06/16 09:00 [medline]
PHST- 2005/05/04 09:00 [entrez]
AID - S0198-8859(05)00043-1 [pii]
AID - 10.1016/j.humimm.2005.01.030 [doi]
PST - ppublish
SO  - Hum Immunol. 2005 Apr;66(4):343-9. doi: 10.1016/j.humimm.2005.01.030.